Literature DB >> 19158668

Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons.

Jesus Bertran-Gonzalez1, Kerstin Håkansson, Anders Borgkvist, Theano Irinopoulou, Karen Brami-Cherrier, Alessandro Usiello, Paul Greengard, Denis Hervé, Jean-Antoine Girault, Emmanuel Valjent, Gilberto Fisone.   

Abstract

The antipsychotic agent haloperidol regulates gene transcription in striatal medium spiny neurons (MSNs) by blocking dopamine D2 receptors (D2Rs). We examined the mechanisms by which haloperidol increases the phosphorylation of histone H3, a key step in the nucleosomal response. Using bacterial artificial chromosome (BAC)-transgenic mice that express EGFP under the control of the promoter of the dopamine D1 receptor (D1R) or the D2R, we found that haloperidol induced a rapid and sustained increase in the phosphorylation of histone H3 in the striatopallidal MSNs of the dorsal striatum, with no change in its acetylation. This effect was mimicked by raclopride, a selective D2R antagonist, and prevented by the blockade of adenosine A2A receptors (A2ARs), or genetic attenuation of the A2AR-associated G protein, Galpha(olf). Mutation of the cAMP-dependent phosphorylation site (Thr34) of the 32-kDa dopamine and cAMP-regulated phosphoprotein (DARPP-32) decreased the haloperidol-induced H3 phosphorylation, supporting the role of cAMP in H3 phosphorylation. Haloperidol also induced extracellular signal-regulated kinase (ERK) phosphorylation in striatopallidal MSNs, but this effect was not implicated in H3 phosphorylation. The levels of mitogen- and stress-activated kinase 1 (MSK1), which has been reported to mediate ERK-induced H3 phosphorylation, were lower in striatopallidal than in striatonigral MSNs. Moreover, haloperidol-induced H3 phosphorylation was unaltered in MSK1-knockout mice. These data indicate that, in striatopallidal MSNs, H3 phosphorylation is controlled by the opposing actions of D2Rs and A2ARs. Thus, blockade of D2Rs promotes histone H3 phosphorylation through the A2AR-mediated activation of Galpha(olf) and inhibition of protein phosphatase-1 (PP-1) through the PKA-dependent phosphorylation of DARPP-32.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158668      PMCID: PMC2758561          DOI: 10.1038/npp.2008.228

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  50 in total

1.  Follicle-stimulating hormone stimulates protein kinase A-mediated histone H3 phosphorylation and acetylation leading to select gene activation in ovarian granulosa cells.

Authors:  L M Salvador; Y Park; J Cottom; E T Maizels; J C Jones; R V Schillace; D W Carr; P Cheung; C D Allis; J L Jameson; M Hunzicker-Dunn
Journal:  J Biol Chem       Date:  2001-08-09       Impact factor: 5.157

2.  MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts.

Authors:  Giselle R Wiggin; Ana Soloaga; Julia M Foster; Victoria Murray-Tait; Philip Cohen; J Simon C Arthur
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

3.  Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum.

Authors:  J C Corvol; J M Studler; J S Schonn; J A Girault; D Hervé
Journal:  J Neurochem       Date:  2001-03       Impact factor: 5.372

Review 4.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

5.  Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties.

Authors:  E Valjent; J C Corvol; C Pages; M J Besson; R Maldonado; J Caboche
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

6.  Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum.

Authors:  D Hervé; C Le Moine; J C Corvol; L Belluscio; C Ledent; A A Fienberg; M Jaber; J M Studler; J A Girault
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

Review 7.  The neurobiology of slow synaptic transmission.

Authors:  P Greengard
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

8.  Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation.

Authors:  P Cheung; K G Tanner; W L Cheung; P Sassone-Corsi; J M Denu; C D Allis
Journal:  Mol Cell       Date:  2000-06       Impact factor: 17.970

9.  The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.

Authors:  J F Chen; R Moratalla; F Impagnatiello; D K Grandy; B Cuellar; M Rubinstein; M A Beilstein; E Hackett; J S Fink; M J Low; E Ongini; M A Schwarzschild
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

10.  Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs.

Authors:  Helen S Bateup; Per Svenningsson; Mahomi Kuroiwa; Shiaoching Gong; Akinori Nishi; Nathaniel Heintz; Paul Greengard
Journal:  Nat Neurosci       Date:  2008-07-11       Impact factor: 24.884

View more
  32 in total

1.  Dopamine D2 receptors gate generalization of conditioned threat responses through mTORC1 signaling in the extended amygdala.

Authors:  D De Bundel; C Zussy; J Espallergues; C R Gerfen; J-A Girault; E Valjent
Journal:  Mol Psychiatry       Date:  2016-01-19       Impact factor: 15.992

2.  Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum.

Authors:  Marco Orrú; César Quiroz; Xavier Guitart; Sergi Ferré
Journal:  Neuropharmacology       Date:  2011-07-05       Impact factor: 5.250

3.  Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32.

Authors:  Emmanuel Valjent; Jesus Bertran-Gonzalez; Heather Bowling; Sébastien Lopez; Emanuela Santini; Miriam Matamales; Alessandra Bonito-Oliva; Denis Hervé; Charles Hoeffer; Eric Klann; Jean-Antoine Girault; Gilberto Fisone
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

4.  ERK/MAPK Signaling Is Required for Pathway-Specific Striatal Motor Functions.

Authors:  Scott R Hutton; James M Otis; Erin M Kim; Yashna Lamsal; Garret D Stuber; William D Snider
Journal:  J Neurosci       Date:  2017-07-21       Impact factor: 6.167

5.  Risperidone effects on heterochromatin: the role of kinase signaling.

Authors:  B Feiner; K A Chase; J K Melbourne; C Rosen; R P Sharma
Journal:  Clin Exp Immunol       Date:  2019-02-03       Impact factor: 4.330

Review 6.  Recent advances in the genetics of dystonia.

Authors:  Jianfeng Xiao; Satya R Vemula; Mark S LeDoux
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

7.  Stimulation of adenosine receptors in the nucleus accumbens reverses the expression of cocaine sensitization and cross-sensitization to dopamine D2 receptors in rats.

Authors:  Benjamin D Hobson; Kathryn E Merritt; Ryan K Bachtell
Journal:  Neuropharmacology       Date:  2012-06-28       Impact factor: 5.250

8.  Role of Gα(olf) in familial and sporadic adult-onset primary dystonia.

Authors:  Satya R Vemula; Andreas Puschmann; Jianfeng Xiao; Yu Zhao; Monika Rudzińska; Karen P Frei; Daniel D Truong; Zbigniew K Wszolek; Mark S LeDoux
Journal:  Hum Mol Genet       Date:  2013-02-27       Impact factor: 6.150

9.  D(2) receptors receive paracrine neurotransmission and are consistently targeted to a subset of synaptic structures in an identified neuron of the crustacean stomatogastric nervous system.

Authors:  Max F Oginsky; Edmund W Rodgers; Merry C Clark; Robert Simmons; Wulf-Dieter C Krenz; Deborah J Baro
Journal:  J Comp Neurol       Date:  2010-02-01       Impact factor: 3.215

Review 10.  Epigenetic mechanisms of drug addiction.

Authors:  Jian Feng; Eric J Nestler
Journal:  Curr Opin Neurobiol       Date:  2013-01-29       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.